These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 21418030)
1. Lipid management for the prevention of cardiovascular disease. Schaefer JR Curr Pharm Des; 2011; 17(9):852-60. PubMed ID: 21418030 [TBL] [Abstract][Full Text] [Related]
2. 2017 Taiwan lipid guidelines for high risk patients. Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI; J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176 [TBL] [Abstract][Full Text] [Related]
3. Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Genest J Can J Cardiol; 2006 Aug; 22(10):863-8. PubMed ID: 16957804 [TBL] [Abstract][Full Text] [Related]
4. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. Hunninghake DB Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501 [TBL] [Abstract][Full Text] [Related]
6. Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials. Hackam DG Am J Cardiovasc Drugs; 2006; 6(6):367-71. PubMed ID: 17192126 [TBL] [Abstract][Full Text] [Related]
7. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
8. [Statins--attaining goal values--with reference to recent studies]. Toplak H; Schallmoser K; DeCampo A Wien Med Wochenschr; 1999; 149(5-6):144-5. PubMed ID: 10408006 [TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol: how low can we go? Sherbet DP; Garg P; Brilakis ES; Banerjee S Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530 [TBL] [Abstract][Full Text] [Related]
11. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913 [TBL] [Abstract][Full Text] [Related]
17. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
18. [Effects of statins on coronary artery disease. Review of the recent publications]. Bednarz B Przegl Lek; 2003; 60(1):27-9. PubMed ID: 12884643 [TBL] [Abstract][Full Text] [Related]
19. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. Sampalis JS; Bissonnette S; Habib R; Boukas S; Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579 [TBL] [Abstract][Full Text] [Related]
20. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. O'Keefe JH; DiNicolantonio JJ; Lavie CJ Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]